NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a ...
Opinion

Netflix Just Got an Extra $2.8 Billion. Here’s What It Should Spend On

Bringing creators onto the streaming giant dramatically expands ad inventory with content that is inherently monetization-friendly.
eLife

Butyrate rescues chlorpyrifos-induced social deficits through inhibition of class I histone deacetylases

Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, United States College of Health Solutions, Arizona State University, Phoenix, United States ...